Abstract: A battery pack, a vehicle and an energy storage device. The battery pack includes at least one battery sequence. The battery sequence includes a plurality of batteries. At least one of the batteries includes a casing and a core packaged in the casing. A gap exists between two neighboring batteries. A ratio of the gap to the thickness of the battery is c, and c satisfies the following relational expression: (a?b)<c<(a×t), where a represents an expansion rate of the battery; b represents a compression rate of the core; and t represents a ratio in percentage of a thickness of the battery after effective compression to a thickness of the battery before compression.

Abstract: An implementation may involve: providing, to an image diffusion model, a prompt that describes characteristics of network traffic; receiving, from the image diffusion model, an image representing the network traffic, wherein the image comprises a matrix of pixel values representing packets of the network traffic in a presence-based format; transforming the pixel values into a trace of the network traffic, wherein the trace encodes at least packet header values of the packets; applying, to the trace, protocol compliance rules that relate to the packet header values; and outputting the trace in a binary format.

Abstract: Disclosed herein are vaccine compositions, in particular, polyvalent icosahedral compositions for antigen presentation. The disclosed compositions may contain an S particle made up of recombinant fusion proteins. The recombinant fusion proteins may include a norovirus (NoV) S domain protein, a linker protein domain operatively connected to the norovirus S domain protein, and an antigen protein domain operatively connected to said linker.

Abstract: Embodiments of voltage regulators that include a power transistor configured to provide a load current, a voltage follower configured to provide a gate voltage of the power transistor, and a circuit configured to transform the gate voltage of the power transistor into a mirror current of the load current and to adjust a current flow through the voltage follower based on the mirror current.

Abstract: A regulator for a load voltage includes a pass transistor for a load current, a gate voltage sensor coupled to a gate of the pass transistor, and a feed-forward supply noise cancellation circuit configured to amplify a gain of a supply noise cancelling signal at increments of the gate voltage.

Abstract: Disclosed herein are vaccine compositions, in particular, polyvalent icosahedral compositions for antigen presentation. The disclosed compositions may contain an S particle made up of recombinant fusion proteins. The recombinant fusion proteins may include a norovirus (NoV) S domain protein, a linker protein domain operatively connected to the norovirus S domain protein, and an antigen protein domain operatively connected to said linker.

Abstract: An online high-precision measuring device for full-size parameters of a wheel set of a rail transit vehicle, includes: a first laser sensor, a second laser sensor, a third laser sensor, and a polygon measuring module that are configured to measure multiple parts of the wheel set. The first laser sensor is arranged on an inner side of a track at a certain angle. The second laser sensor is arranged below the track at a certain angle. The third laser sensor is arranged on an outer side of the track at a certain angle. The polygon measuring module is butted with the track. The device can realize online pass-through non-stop measurement of the full-size parameters of the wheel set of the rail transit train accurately, such as tread wear, equivalent conicity and wheel polygon.

Abstract: A finishing boring machine for a high-precision wheel hub hole, includes: a boring machine body, a hydraulic automatic centering fixture, a computer numerical control (CNC) vertical sliding table, a spindle box, a CNC facing head, a cutter assembly, and a hydraulic system. The boring machine body is a main structure of the finishing boring machine for the wheel hub hole. The hydraulic automatic centering fixture is configured to place a to-be-processed workpiece, and is arranged on the boring machine body. The CNC vertical sliding table is configured to control operation of the CNC facing head, and is arranged on the boring machine body. The spindle box is configured to control an operation speed of the CNC facing head, and is arranged on the CNC vertical sliding table. The CNC facing head is configured to control the cutter assembly to process the to-be-processed workpiece, and is arranged on the spindle box.

Abstract: A method of treating a subject suffering from a condition characterized by over-expression of Ten-eleven translocation 1 (TET1) is provided, the method including administering to the subject an effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the Formula I: wherein: R1, R2, R3, R4, and R5 are each independently selected from the group consisting of H, hydroxyl, alkyl, alkoxy, amine, halo, and trifluoromethyl, and wherein any two adjacent moieties of R1, R2, R3, R4, and R5 may come together to form a heterocyclic ring; R6 is H or hydroxyl; and R7 is selected from H, wherein R8 is C or O. Also provided are methods for selectively suppressing transcription of TET1 and/or reducing a level of 5-hydroxymethylcytosine in a subject by administering an effective amount of a Formula I compound and pharmaceutical compositions comprising Formula I compounds.

Abstract: A nanoparticle delivery system designed for sustained delivery of microRNA-150 (miR-150) to FLT3-overexpressing acute myeloid leukemia (AML) cells, the delivery system comprising poly(amidoamine) (PAMAM) dendrimers complexed with miR-150, wherein at least one dendrimer is surface-functionalized with a ligand specific for FLT3 receptor, and methods for treating AML characterized by FLT3-overexpression are provided.

Abstract: A battery pack, a vehicle and an energy storage device. The battery pack includes at least one battery sequence. The battery sequence includes a plurality of batteries. At least one of the batteries includes a casing and a core packaged in the casing. A gap exists between two neighboring batteries. A ratio of the gap to the thickness of the battery is c, and c satisfies the following relational expression: (a?b)<c<(a×t), where a represents an expansion rate of the battery; b represents a compression rate of the core; and t represents a ratio in percentage of a thickness of the battery after effective compression to a thickness of the battery before compression.

Abstract: A cell array, including a plurality of cells arranged in sequence is provided. Each of the plurality of cells includes a housing and an electrode core. The electrode core includes an electrode plate. The electrode plate includes a current collector and a coating layer arranged on the current collector. The cell array satisfies the following formula 1: (1?JRw)+(SRw?1)=10%?15%. JRw is an expansion space for the electrode core inside each of the plurality of cells in a first direction, SRw is an expansion space outside the plurality of cells in the first direction, and a thickness direction of each of the plurality of cells is defined as the first direction. JRw=Pw/(Cellw?Kw?Cw). SRw=(Mw?MNw)/(Celln×Cellw).

Abstract: A method of treating a subject suffering from a condition characterized by over-expression of Ten-eleven translocation 1 (TET1) is provided, the method including administering to the subject an effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the Formula I: wherein: R1, R2, R3, R4, and R5 are each independently selected from the group consisting of H, hydroxyl, alkyl, alkoxy, amine, halo, and trifluoromethyl, and wherein any two adjacent moieties of R1, R2, R3, R4, and R5 may come together to form a heterocyclic ring; R6 is H or hydroxyl; and R7 is selected from H, wherein R8 is C or O. Also provided are methods for selectively suppressing transcription of TET1 and/or reducing a level of 5-hydroxymethylcytosine in a subject by administering an effective amount of a Formula I compound and pharmaceutical compositions comprising Formula I compounds.

Abstract: A method of treating a subject suffering from a condition characterized by over-expression of Ten-eleven translocation 1 (TET1) is provided, the method including administering to the subject an effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the Formula I: wherein: R1, R2, R3, R4, and R5 are each independently selected from the group consisting of H, hydroxyl, alkyl, alkoxy, amine, halo, and trifluoromethyl, and wherein any two adjacent moieties of R1, R2, R3, R4, and R5 may come together to form a heterocyclic ring; R6 is H or hydroxyl; and R7 is selected from H, wherein R8 is C or O. Also provided are methods for selectively suppressing transcription of TET1 and/or reducing a level of 5-hydroxymethylcytosine in a subject by administering an effective amount of a Formula I compound and pharmaceutical compositions comprising Formula I compounds.

Abstract: A nanoparticle delivery system designed for sustained delivery of microRNA-150 (miR-150) to FLT3-overexpressing acute myeloid leukemia (AML) cells, the delivery system comprising poly(amidoamine) (PAMAM) dendrimers complexed with miR-150, wherein at least one dendrimer is surface-functionalized with a ligand specific for FLT3 receptor, and methods for treating AML characterized by FLT3-overexpression are provided.

Abstract: A nanoparticle delivery system designed for sustained delivery of microRNA-150 (miR-150) to FLT3-overexpressing acute myeloid leukemia (AML) cells, the delivery system comprising poly(amidoamine) (PAMAM) dendrimers complexed with miR-150, wherein at least one dendrimer is surface-functionalized with a ligand specific for FLT3 receptor, and methods for treating AML characterized by FLT3-overexpression are provided.

Abstract: The invention relates to reagents and methods that allow the expression of an active NifB protein in yeast and plants under aerobic conditions. The active NifB protein allows the in vitro synthesis of the FeMo cofactor (FeMo-co) which leads to the subsequent apo-NifDK activation and generation of active nitrogenase.

Abstract: Provided are a heterocyclic carboxylic acid amide ligand and applications thereof in a copper catalyzed coupling reaction. Specifically, provided are uses of a compound represented by formula (I), definitions of radical groups being described in the specifications. The compound represented by formula (I) can be used as the ligand in the copper catalyzed coupling reaction of the aryl halogeno substitute, and is used or catalyzing the coupling reaction for forming the aryl halogeno substitute having C—N, C—O, C—S and other bonds.

Abstract: The server may be configured with two or more than two network cards. The server may advertise a route, which may comprise a network segment address of each local network card and an IP address of the server, to a route neighbor of the server via the each local network card. The server may receive route information, which may comprise an address of a device, from the route neighbor of the server via the each network card. The server may determine a route from the server to the device. An outgoing port of the route may be the each network card. When a packet destined for the address of the device is received, the server may forward the packet via the route. When a link connecting to a network card fails, the server may disable all the routes, outgoing interfaces of which may be the network card.

Abstract: A method of treating a subject suffering from a condition characterized by over-expression of Ten-eleven translocation 1 (TET1) is provided, the method including administering to the subject an effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the Formula I: (formula I) wherein: R1, R2, R3, R4, and R5 are each independently selected from the group consisting of H, hydroxyl, alkyl, alkoxy, amine, halo, and trifluoromethyl, and wherein any two adjacent moieties of R1, R2, R3, R4, and R5 may come together to form a heterocyclic ring; R6 is H or hydroxyl; and R7 is selected from H, (formula 2), and (formula 3), wherein R8 is C or O. Also provided are methods for selectively suppressing transcription of TET1 and/or reducing a level of 5-hydroxymethylcytosine in a subject by administering an effective amount of a Formula (I) compound and pharmaceutical compositions comprising Formula (I) compounds.